Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Duchenne muscular dystrophy (DMD) is a severe childhood neuromuscular disorder caused by DMD gene mutations.
• These mutations disrupt dystrophin protein production, leading to muscle degeneration and premature death.

Purpose of the Study:

• To review the current status of antisense oligonucleotide (AO)-mediated exon skipping therapy for DMD.
• To discuss preclinical, clinical, and regulatory challenges and potential solutions for AO therapy translation.

Main Methods:

• Review of existing literature on AO-mediated exon skipping for DMD.
• Analysis of preclinical studies, clinical trial progress, and identified therapeutic hurdles.

Main Results:

• AO therapy can restore dystrophin production by inducing exon skipping in DMD pre-mRNA.
• Rapid progress has been made from initial studies to ongoing Phase II and III clinical trials.

Conclusions:

• AO-mediated exon skipping is a potential disease-modifying treatment for DMD.
• Addressing mutation heterogeneity, systemic delivery, and cardiac targeting are crucial for clinical success.